BIRMINGHAM, Ala., Sept. 17 /PRNewswire/ — Detailed cholesterol
testing for Type 2 diabetes patients is the focus of a newly
published article by Atherotech Diagnostics Lab Chief Medical
Officer Michael E. Cobble, M.D. “Advanced Lipid Testing” appears in
the September/October 2010 quarterly issue of Practical
Diabetology.
(Photo: http://photos.prnewswire.com/prnh/20091228/LA30526)
(Photo: http://www.newscom.com/cgi-bin/prnh/20091228/LA30526)
The article discusses the clinical advantages of advanced
cholesterol testing in reducing cardiovascular disease (CVD) risk
in patients with Type 2 diabetes and details several currently
available advanced lipid tests, including the VAP® Cholesterol
Test from Atherotech. Cobble also explores which patients are
appropriate to test and how to apply advanced lipid testing
results.
Advanced lipid testing is affordable, widely available and may
provide valuable information in the treatment and management of
people living with Type 2 diabetes, explained Cobble, who is also a
director, researcher and clinician at Canyons Medical Center in
Sandy, Utah.
“We know that aggressive management of multiple cardiovascular
disease risks in diabetes mellitus patients has proven beneficial,”
Cobble said. “But in order to properly treat these patients, we
first must identify them and effectively assess their risk. This is
achieved through advanced lipid profiles.”
Diabetes is a high-risk CVD condition that affects more than 24
million Americans, and patients with Type 2 diabetes are considered
high risk due to traditional CVD risk factors and residual lipid
risk factors, all of which can be determined through detailed
lipoprotein assays such as the VAP Test.
“Standard lipid tests miss more than half of all at-risk
patients, and may actually
‘/>”/>
